Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.

Biochimica et biophysica acta - 1 Oct 2009

Flores María Victoria, Strawbridge Joanne, Ciaramella Giuseppe, Corbau Romuald

Abstract excerpt

Existing HCV protease inhibitors fall into two categories: reversible and non-covalent, such as BILN-2061, and covalent and reversible, exemplified by SCH-503034 and VX-950. In this work, the characterization of the kinetics of these three inhibitors is presented. SCH-503034 and VX-950 initially bind to the genotype 1b HCV NS3/4A protease to form a low affinity complex, with K(i) values of 5 and 5.8 microM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Macrocyclic Compounds
Share to Carbamates
Share to Half-Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligopeptides

Share to Proline

Share to Quinolines

Share to Serine Proteinase Inhibitors

Share to Thiazoles

Source

Identifiers

PMID: 19505593
DOI: 10.1016/j.bbapap.2009.06.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.PMID 19505593Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.Semantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.Semantic proximity Read ↗

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.Semantic proximity Read ↗

Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.Semantic proximity Read ↗

Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.Semantic proximity Read ↗

Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.Semantic proximity Read ↗

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.Semantic proximity Read ↗

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeSemantic proximity Read ↗

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.Semantic proximity Read ↗

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.